Nosocomial infections in neutropenic cancer patients.
OBJECTIVE
Identification of overall and site-specific rates of nosocomial infection in neutropenic patients with cancer and associated pathogens.


METHODS
Cumulative continuous prospective surveillance over a 42-month period. Criteria and definitions of infection in neutropenic patients (absolute neutrophil counts < 1,000/mm3) were developed, and surveillance was carried out by a certified infection control nurse and a senior oncology research fellow.


METHODS
A cancer research center with two designated oncology nursing units.


METHODS
Neutropenic patients with hematological and solid malignancies undergoing high-dose chemotherapy with and without autologous bone marrow transplantation. All patients admitted to both of the units during the study period were surveyed. Those who developed neutropenia are included in this report.


RESULTS
A total of 444 nosocomial infections were identified in 920 neutropenic patients during 9,582 days of neutropenia for an overall rate of 48.3 per 100 neutropenic patients, or 46.3 per 1,000 days at risk. The rate of bloodstream infection per 100 neutropenic patients was 13.5 (gram-positive, 9.2; gram-negative, 4.8; and Candida 1.2). Other site-specific rates were: urinary tract, 5.7; respiratory tract, 5.5; thrush, 6.6; skin, 3.4; and gastrointestinal tract, 3.4. Among 392 pathogens identified, there were 137 (35%) gram-positive cocci, 105 (27%) gram-negative rods, 70 (18%) Candida, 37 (9%) gram-positive rods, 22 (6%) viruses, and 15 (4%) Aspergillus.


CONCLUSIONS
The rate of both overall and site-specific nosocomial infections in neutropenic patients is high. Neutropenia is a significant intrinsic risk factor that should be addressed in surveillance programs. Infection control and infectious diseases practitioners may need to modify techniques for surveillance, control, and management of infection in this population.
Carlisle
P S
PS
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.
Gucalp
R
R
Wiernik
P H
PH
D000328:Adult; D003428:Cross Infection / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D017053:Infection Control; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D009519:New York City / Q000453:epidemiology; D011159:Population Surveillance; D011446:Prospective Studies; D012307:Risk Factors